Risk nomogram for assessing renal recovery in patients with newly diagnosed multiple myeloma-related renal impairment

被引:0
|
作者
Li, Shaobo [1 ,2 ]
Zhang, Min [3 ]
Liu, Jin [4 ]
Liu, Shaojun [3 ]
Zhu, Chen [1 ]
Shang, Da [3 ]
Guan, Yi [3 ]
Wang, Qian [1 ]
机构
[1] Fudan Univ, Huashan Hosp, Dept Hematol, Shanghai 200040, Peoples R China
[2] Inner Mongolia Med Univ, Peking Univ Canc Hosp, Dept Nucl Med, Affiliated Canc Hosp, Inner Mongolia Campus, Hohhot 010020, Peoples R China
[3] Fudan Univ, Huashan Hosp, Dept Nephrol, Shanghai 200040, Peoples R China
[4] Naval Med Univ, Changzheng Hosp, Dept Hematol Myeloma & Lymphoma Ctr, Shanghai 200003, Peoples R China
关键词
Multiple myeloma; Myeloma nephropathy; Renal impairment recovery; Risk nomogram; BORTEZOMIB-BASED CHEMOTHERAPY; CAST NEPHROPATHY; STAGING SYSTEM; HIGH-CUTOFF; FAILURE; HEMODIALYSIS; DISEASE; SAFETY; INDEPENDENCE; MULTICENTER;
D O I
10.1016/j.currproblcancer.2023.100962
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To determine risk factors affecting renal recovery in newly diagnosed multiple myeloma (NDMM) patients with renal impairment (RI) and establish a risk nomogram. This multi-center, retrospective cohort study included 187 NDMM patients with RI, 127 of whom were admitted to Huashan Hospital and assigned to the training cohort and 60 were admitted to Changzheng Hospital and assigned to the external validation cohort. The baseline data of the 2 cohorts were compared, and survival and renal recovery rates were analyzed. Independent risk factors affecting renal recovery were determined by binary logistic regression analysis, and a risk nomogram was established and subsequently tested in the external validation cohort. Results: The median overall survival (OS) improved in patients who achieved renal recovery etc within 6 courses of MM directed treatment compared with patients without renal recovery. Median time to renal recovery was 2.65 courses, and the cumulative renal recovery rate during the first 3 courses was 75.05%. Involved serum free light chain (sFLC) ratio of > 120 at diagnosis, time from renal impairment to treatment > 60 days, and a hematologic response without a very good partial remission (VGPR) or better resulted as independent risk factors for renal recovery during the first 3 courses. The established risk nomogram had good discriminative ability and accuracy. Involved sFLC was a key factor affecting renal recovery. Starting treatment as soon as possible after detecting RI and achieving deep hematologic remission during the first 3 courses of treatment helped achieve renal recovery and improve prognosis.(c) 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment
    Yang, Guangzhong
    Chen, Wenming
    Wu, Yin
    CHINESE JOURNAL OF CANCER RESEARCH, 2013, 25 (02) : 155 - 160
  • [22] Impact of Kidney Impairment Recovery on Survival of Patients with Newly Diagnosed Multiple Myeloma
    Strufaldi, Fernando Louzada
    Lutf, Luciana Gil
    Caires, Renato A.
    Mattedi, Francisco Zanotelli
    Costalonga, Elerson
    Seguro, Fernanda S.
    Martinez, Gracia A.
    Costa e Silva, Veronica Torres
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [23] Lack of Renal Recovery Predicts Poor Survival in Patients of Multiple Myeloma With Renal Impairment
    Sharma, Rintu
    Jain, Arihant
    Jandial, Aditya
    Lad, Deepesh
    Khadwal, Alka
    Prakash, Gaurav
    Nada, Ritambhra
    Aggarwal, Ritu
    Ramachandran, Raja
    Varma, Neelam
    Malhotra, Pankaj
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (08): : 626 - 634
  • [24] Renal Outcomes and Predictive Analysis of Progression in Newly Diagnosed Multiple Myeloma Patients
    Lalwani, Devansh
    Khan, Hamza
    Nair, Aditya
    Mishra, Dhyey
    Shah, Jash
    Nabar, Leeladhar
    Talati, Shriraj
    Tembhare, Prashant
    Nayak, Lingaraj
    Shetty, Alok
    Rajpal, Sweta
    Chatterjee, Gaurav
    Khan, Ajmat
    Mirgh, Sumeet
    Jindal, Nishant
    Gokarn, Anant
    Punatar, Sachin
    Jain, Hasmukh
    Patkar, Nikhil
    Shetty, Dhanlaxmi
    Subramanian, Papagudi
    Gujral, Sumeet
    Bagal, Bhausaheb
    Sengar, Manju
    Khattry, Navin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S233 - S234
  • [25] Carfilzomib Is Safe and Effective in Newly Diagnosed Patients with Multiple Myeloma with Renal Involvement
    Diamond, Benjamin
    Jayabalan, David S.
    Pearse, Roger
    Perry, Art
    Pekle, Karen
    Niesvizky, Ruben
    Rossi, Adriana C.
    BLOOD, 2017, 130
  • [26] SIGNIFICANT IMPROVEMENT IN RENAL FUNCTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA
    Ismail, I.
    Saponara, A.
    Mantha, M.
    Bavishi, K.
    Dheda, S.
    NEPHROLOGY, 2018, 23 : 69 - 69
  • [27] Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
    Zhang, Yue
    Chen, Xiao-Lei
    Chen, Wen-Ming
    Zhou, He-Bing
    BIOMED RESEARCH INTERNATIONAL, 2019, 2019
  • [28] The Role of Novel Agents on Reversibility of Renal Impairment in Newly Diagnosed Patients with Multiple Myeloma; a Single Center Experience on 112 Patients
    Dimopoulos, Meletios A.
    Roussou, Maria
    Gkotzamanidou, Maria
    Psimenou, Erasmia
    Mparmparoussi, Despoina
    Matsouka, Charis
    Terpos, Evangelos
    Kastritis, Efstathios
    BLOOD, 2011, 118 (21) : 1694 - 1694
  • [29] Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma
    W I Gonsalves
    N Leung
    S V Rajkumar
    A Dispenzieri
    M Q Lacy
    S R Hayman
    F K Buadi
    D Dingli
    P Kapoor
    R S Go
    Y Lin
    S J Russell
    J A Lust
    S Zeldenrust
    R A Kyle
    M A Gertz
    S K Kumar
    Blood Cancer Journal, 2015, 5 : e296 - e296
  • [30] Improvement in Renal Function and Its Impact on Survival in Patients with Newly Diagnosed Multiple Myeloma
    Gonsalves, Wilson I.
    Leung, Nelson
    Rajkumar, S. Vincent
    Dispenzieri, Angela
    Buadi, Francis
    Lacy, Martha Q.
    Dingli, David
    Kapoor, Prashant
    Go, Ronald S.
    Lust, John A.
    Hayman, Suzanne R.
    Lin, Yi
    Zeldenrust, Steven R.
    Kyle, Robert A.
    Gertz, Morie A.
    Kumar, Shaji
    BLOOD, 2014, 124 (21)